AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Canandaigua National Trust Co of Florida

Canandaigua National Trust Co of Florida trimmed its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 41.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,176 shares of the company’s stock after selling 2,971 shares during the quarter. Canandaigua National Trust Co of Florida’s holdings in AstraZeneca were worth $274,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in AZN. Private Advisor Group LLC raised its position in shares of AstraZeneca by 7.5% during the 2nd quarter. Private Advisor Group LLC now owns 65,105 shares of the company’s stock worth $5,078,000 after purchasing an additional 4,555 shares during the period. Advisor OS LLC increased its position in AstraZeneca by 4.2% in the 2nd quarter. Advisor OS LLC now owns 5,617 shares of the company’s stock valued at $438,000 after acquiring an additional 226 shares during the period. Cobblestone Capital Advisors LLC NY increased its position in AstraZeneca by 4.6% in the 2nd quarter. Cobblestone Capital Advisors LLC NY now owns 3,529 shares of the company’s stock valued at $275,000 after acquiring an additional 154 shares during the period. Norden Group LLC increased its position in AstraZeneca by 31.3% in the 2nd quarter. Norden Group LLC now owns 4,932 shares of the company’s stock valued at $385,000 after acquiring an additional 1,175 shares during the period. Finally, Custom Index Systems LLC acquired a new stake in AstraZeneca in the 2nd quarter valued at approximately $215,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AZN traded up $0.59 during trading hours on Monday, hitting $66.84. 5,353,299 shares of the company were exchanged, compared to its average volume of 3,999,309. The company has a market capitalization of $207.25 billion, a PE ratio of 31.98, a PEG ratio of 1.19 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a fifty day simple moving average of $66.77 and a 200-day simple moving average of $75.30. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.87 earnings per share. As a group, sell-side analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on AZN. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.